About
Executive Management
Board of Directors
Scientific Advisory Board
Science
Overview
Publications
Pipeline
Investors
Contact
About
Executive Management
Board of Directors
Scientific Advisory Board
Science
Overview
Publications
Pipeline
Investors
Contact
Home
>
News
>
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
October 13, 2021
Introduction to SAB’s Unique DiversitAb™ Immunotherapy Platform
Share
SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021
October 6, 2021
SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19
October 4, 2021
SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer
September 28, 2021
